Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads
Journal of Medicinal Chemistry · 12.09.2024 · 67 (17) · 15756-15779
DOI: 10.1021/acs.jmedchem.4c01384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.08.2024. Verfasst von Akash M Patel und 22 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Chemistry, Merck & Co. Inc., South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Toll-Like Receptor 8, Immunoconjugates, Drug Design. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Toll-like receptors 7 and 8 are involved in modulating the adaptive and innate immune responses, and their activation has shown promise as a therapeutic strategy in the field of immuno-oncology. While systemic exposure to TLR7/8 agonists can result in poor tolerance, combination therapies and targeted delivery through antibody-drug conjugates (ADCs) can help mitigate adverse effects. Described herein is the identification of a novel and potent series of pyrazolopyrimidine-based TLR7/8 agonists with tunable receptor selectivity. Representative agonists from this series were successfully able to induce the production of various proinflammatory cytokines and chemokines from human peripheral blood mononuclear cells. Anti-HER2-25 and anti-HER2-26 ADCs made from this class of payloads demonstrated mechanism-based activation of TLR7/8 in a THP1/N87 coculture system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Discovery Chemistry, Merck & Co. Inc., South San Francisco, California 94080, United States.
- Discovery Biologics, Merck & Co. Inc., South San Francisco, California 94080, United States.
- Modeling and Informatics, Merck & Co. Inc., South San Francisco, California 94080, United States.
- Discovery Oncology, Merck & Co. Inc., South San Francisco, California 94080, United States.
- External Discovery Chemistry, Merck & Co. Inc., South San Francisco, California 94080, United States.
ORCID-Profile: Akash M Patel, Alan C Cheng, Natalia Chernyak, Rimsha Mehmood, Scott A Hollingsworth, Simon B Lang, W Michael Seganish
Zitieren
APA
Patel, A. M., Willingham, A., Cheng, A. C., Tomazela, D., Bowman, E., Kofman, E., Zhang, F., Bao, J., Sanzone, J. R., Choy, J. W., Flygare, J. A., Han, J. H., Pradhan, K., Kieffer, M., Chernyak, N., Akbari, P., Liu, P., Mehmood, R., Naravula, S., …, & Seganish, W. M. (2024). Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads. Journal of Medicinal Chemistry, 67(17), 15756-15779. https://doi.org/10.1021/acs.jmedchem.4c01384
Vancouver
Patel AM, Willingham A, Cheng AC, Tomazela D, Bowman E, Kofman E, et al. Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads. Journal of Medicinal Chemistry. 2024;67(17):15756-15779. doi:10.1021/acs.jmedchem.4c01384
BibTeX
@article{Patel2024,
author = {Patel, Akash M and Willingham, Aarron and Cheng, Alan C and Tomazela, Daniela and Bowman, Eddie and Kofman, Esther and Zhang, Fan and Bao, Jianming and Sanzone, Jillian R and Choy, Jonathan W and Flygare, John A and Han, Jin-Hwan and Pradhan, Komal and Kieffer, Madeleine and Chernyak, Natalia and Akbari, Peyman and Liu, Ping and Mehmood, Rimsha and Naravula, Saraswathi and Hollingsworth, Scott A and Bhagwat, Bhagyashree and Lang, Simon B and Seganish, W Michael},
title = {Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {17},
pages = {15756--15779},
doi = {10.1021/acs.jmedchem.4c01384}
}
EUVIMED